A JAK-inhibitor cream cleared skin in lichen planus, in a small early trial
Ruxolitinib cream beat a placebo cream for cutaneous lichen planus over 16 weeks, but the phase 2 trial randomised only 64 patients and was funded by the drug's maker.
Brepocitinib 30 mg beat placebo in dermatomyositis; 15 mg did not
The phase 3 VALOR trial met its primary endpoint at the higher dose of the oral TYK2-JAK1 inhibitor, with more serious infections — a benefit and a safety signal that arrive together.
JAK inhibitors regrow hair in severe alopecia areata. About a third reach the endpoint
In two phase 3 trials, 38.8% and 35.9% on baricitinib 4 mg reached near-complete scalp regrowth at 36 weeks against 6.2% and 3.3% on placebo — the first drug class to do this for the condition.
Biologics changed severe eczema. About a third of patients reach clear or near-clear skin
In the two pivotal dupilumab trials, 36% to 38% reached that endpoint at 16 weeks against 8% to 10% on placebo. A 97-trial network review finds the newer drugs clustered closely together.
In giant cell arteritis, stopping upadacitinib at a year let disease roar back
Patients in remission who stayed on the JAK inhibitor through a second year flared far less than those switched to placebo — 7.4% versus 59.5% — in an extension of the SELECT-GCA trial.